Advice

Recommended for restricted use within NHS Scotland.

RECOMMENDATION

Transdermal fentanyl should be considered as a second-line alternative for patients with intractable pain due to non malignant conditions. It should be reserved for patients whose pain has initially been controlled by oral means, the pain being relatively stable. Its use should focus on such patients who have difficulty swallowing or have problems with opiate induced constipation.

NB: Transdermal patches are significantly more expensive than oral therapy.

Download detailed advice18KB (PDF)

Download

Medicine details

Medicine name:
Fentanyl transdermal (Durogesic®)
SMC ID:
24/02
Indication:
Chronic intractable pain
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Central nervous system
Submission type
Full
Status
Restricted
Date advice published
10 January 2003